Donor T cells recognizing hematopoiesis-restricted minor histocompatibility antigens (mHags) HA-1 and HA-2 on malignant cells play a role in the antileukemia effect of donor lymphocyte infusion (DLI) in patients with relapsed leukemia after allogeneic stem cell transplantation. We quantified the contribution of HA-1 and HA-2 specific T cells to the total number of leukemia-reactive T cells in three HA-2 and/or HA-1 positive patients responding to DLI from their mHag negative donors. Clinical responses occurring 5-7 weeks after DLI were accompanied by an increase in percentages HLA-DR expressing T cells within the CD8
Introduction
Adoptive immunotherapy with donor lymphocyte infusion (DLI) is an effective treatment for patients with relapsed hematological malignancies after allogeneic stem cell transplantation (SCT). [1] [2] [3] [4] However, the beneficial graft-versus-leukemia (GVL) effect of DLI is often associated with a high incidence of graft-versus-host disease (GVHD) and treatment-related mortality. [5] [6] [7] [8] Following HLA-identical SCT, donor-derived T cells recognizing minor histocompatibility antigens (mHags) on recipient cells are considered to play an important role in the antileukemic effect observed after DLI. mHags are immunogenic peptides derived from polymorphic intracellular proteins. Some mHags, including mHags HA-3, HA-4, HA-6, HA-7, 9,10 HA-8 11 and the male specific HY antigens, 9, [12] [13] [14] [15] [16] [17] are ubiquitously expressed in most or all tissues, whereas others, like the hematopoiesis restricted mHags HA-1 9, 18 and HA-2 9, 19 and the B cell lineage restricted mHag HB-1, 20 are selectively expressed. mHag specific T cells can recognize and lyse leukemic cells, and are capable of growth inhibition of leukemic progenitor cells. [21] [22] [23] [24] The clinical effect of the immune response to mHags is at least partly determined by the tissue distribution of mHags. T cell responses to ubiquitously expressed mHags can induce GVL but may also cause severe GVHD, as has been shown for the male specific HY antigens. Male patients receiving an SCT from a female donor have a lower incidence of leukemic relapse but also a higher risk of developing GVHD. 25 In contrast, T cell responses to mHags like HA-1 and HA-2, which are selectively expressed on hematopoietic cells, including malignant hematopoietic cells of both lymphoid and myeloid origin, 9, 21, 22, 26 may induce GVL with a more limited risk of GVHD, although a correlation between the presence of HA-1 disparity between donor and recipient and GVHD after SCT has been found in some studies. 27, 28 The involvement of the hematopoiesis restricted mHag HA-1 in GVHD can be explained by the expression of HA-1 on professional antigen-presenting (APC) cells including dendritic cells and Langerhans cells. 29 In a murine allogeneic bone marrow transplantation model it has been demonstrated that recipient-derived APC may present the initial target antigens for triggering GVHD. 30 In a skin-explant model, it was demonstrated that HA-1 specific cytotoxic T lymphocyte (CTL) do not directly attack nonhematopoietic cells and target tissues of GVHD. 31 Despite the large number of polymorphic genes present in the human genome, the actual number of mHags defined as polymorphic peptides capable of eliciting an in vivo immune response seems to be limited. T cell responses against some mHags, including HA-1 and HA-2 and the male specific HY antigens, have been detected in many patients treated with SCT from mHag incompatible donors, suggesting that these mHags are immunodominant within the overall antihost immune response. [32] [33] [34] Based on the tissue distribution of the HLA-A2 restricted mHags HA-1 and HA-2, we hypothesized that HA-1 and HA-2 specific T cells may play a significant role in inducing GVL without GVHD following DLI. Recently, we have shown by HA-1 and HA-2 tetramer staining a direct association between the emergence of HA-1 and HA-2 tetramer þ T cells in peripheral blood (PB) of patients successfully treated with DLI from their HA-2 and/or HA-1 disparate donor, and the disappearance of malignant recipient cells. However, as was measured by the coexpression of HLA-DR, other activated CD4 þ and CD8 þ T cells not specific for HA-1 or HA-2 were also present in these patients during the clinical response and may have contributed to the eradication of the malignancy. 35 The aim of the present study was to quantify the relative contribution of HA-1 and HA-2 specific T cells within the total number of leukemia-directed T cells in patients treated with DLI from HA-1 or HA-2 negative donors. T cells were isolated from the PB of the patients at the time of clinical response to DLI, and stimulated with bone marrow (BM) containing malignant cells obtained from the patient prior to transplantation. The method most frequently used for the in vitro analysis of leukemiareactive T cell responses is the generation of T cell lines and subsequent cloning of T cells by limiting dilution. However, this method requires extensive in vitro culture periods, and may preferentially select for precursor T cells with the capacity to survive and proliferate most optimally in vitro possibly resulting in selective isolation of a limited repertoire that does not accurately reflect the overall immune response. Therefore, we directly analyzed at a clonal level the overall immune response directed against the malignancy. T cells responding to the malignancy by secreting IFNg were isolated from PB, directly cloned and expanded, and the frequencies of HA-2, HA-1 and/ or HY specific CTL clones, their function and TCR BV usages were analyzed. Our study shows that during the clinical response to DLI from HA-2 and/or HA-1 disparate donors, a high percentage of the leukemia-reactive T cells in the recipients was directed against HA-1 or HA-2 demonstrating the immunodominant nature of these mHags. These HA-1 and HA-2 specific CTL clones were capable of lysing leukemic cells and antigen-specific inhibition of leukemic progenitor cell growth illustrating their biological significance. Furthermore, we show that HA-1 and HA-2 specific T cells could be generated from PB of the unprimed HLA-A2 þ , HA-1 and/or HA-2 negative donors. In conclusion, this study supports the hypothesis that adoptive immunotherapy with donor-derived HA-1 or HA-2 specific CTL may be used to more specifically eliminate the leukemic cells after allogeneic SCT.
Materials and methods

Patients and preparation of blood and BM samples
Three patients treated with DLI for relapse of the hematological malignancy after allogeneic SCT were included in this study. Characteristics of the donor-recipient pairs, including hematological disease, sex, HLA class I typing, expression of mHags HA-1, HA-2 and HY, are shown in Table 1 . After informed consent, BM was obtained from the patients before SCT, and PB samples were obtained before and at regular intervals after DLI. PB and BM were also obtained from the HLA-identical sibling donors. Mononuclear cells were isolated from the samples by Ficoll-Isopaque separation, and cryopreserved for future use.
Stable Epstein-Barr Virus (EBV)-transformed B cell lines (EBV-LCL) and phytohemagglutinin (PHA)-activated T cells (PHA blasts) were generated as described previously. 23 
Analysis of BCR/ABL positive cells in PB and BM
Real-time BCR/ABL PCR analysis was performed using an ABI/ Prism s 7700 sequence-detector system (Applied Biosystems, Foster City, USA) as described previously. 36 . The detection limit of this assay is a BCR/ABL to porphobilino-gen deaminase (PBGD) ratio of 10
À5
. BCR/ABL fluorescence in situ hybridization was performed as described by using locus-specific identifier BCR/ABL extra signal probes (Vysis, Downers Grove, USA). 37 Classical cytogenetic analysis was performed by GTGbanding.
Phenotypic analysis and tetramer staining of PB mononuclear cells and cytotoxic T cell clones
To determine the percentage of circulating HLA-DR þ T cells in the patient, PBMC were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD3 (Becton Dickinson (BD), San Jose, USA), phycoerythrin (PE)-conjugated anti-HLA-DR (BD) and Cy5-conjugated anti-CD8 (DAKO, Glostrup, Denmark) or Cy5-conjugated anti-CD4 (CLB, Amsterdam, The Netherlands) monoclonal antibodies. Isolated T cell clones were incubated with FITC-conjugated anti-CD3, PE-conjugated anti-CD4 (Caltag, Burlingame, USA) and Cy5-conjugated anti-CD8.
PE-labeled tetrameric complexes of HA-1 and HA-2 bound to HLA-A2 molecules were prepared as described previously. 38 Additionally, tetrameric complexes of HY peptides, derived from the SMCY gene, bound to HLA-A2 or HLA-B7 molecules were constructed. The percentage of tetramer þ T cells in the patient PBMC was determined by staining with the PE-labeled tetramers and Cy5-conjugated anti-CD8 antibodies for 30 min at 41C. T cell clones were stained with the PE-labeled tetramers without counterstaining. After labeling all cell samples were analyzed on a FACSCalibur (BD).
Isolation of in vivo primed leukemia-reactive T cell clones
To isolate functional T cells that responded to the leukemia, T cells were purified from the peripheral blood mononuclear cells (PBMC) from the recipient or, in selected experiments, from the donor by negative selection using the pan T isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), according to the manufacturer's instructions. After selection the T cell enriched fractions consisted of 78-90% CD3 þ cells. Quantities of 0.5 Â 10 6 -2.5 Â 10 6 purified T cells were stimulated with equal numbers of irradiated (15 Gy) BM cells isolated from the recipients prior to transplantation. The BM cells from patient 1 contained approximately 10% plasma cells. The BM cells from patient 2 and 3 were taken at the time of chronic phase chronic myeloid leukemia (CML) with cytogenetics showing t(9;22) translocation and trisomy 8, and t(9;22) translocation in all metaphases, respectively. The cell suspensions were cultured at a final cell concentration of 10 6 cells per ml in IMDM 
Expression of mHags HA-1 and HA-2 was determined by genomic mHag typing. M ¼ male, F ¼ female.
Dominance of HA-1 and HA-2 specific T cells after DLI FM Kloosterboer et al (BioWhittaker, Verviers, Belgium) containing 10% human serum (culture medium). After 16 h of stimulation at 371C the cells were harvested, and IFNg secreting T cells were stained using the IFNg secretion assay (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's instructions, and isolated by single cell/well FACsorting. Briefly, the cells were washed in cold buffer (phosphate-buffered saline (PBS) containing 0.5% human albumine and 2 mM EDTA), resuspended in cold culture medium, and 20 ml IFNg catch reagent containing anti-CD45 antibody/anti-IFNg-antibody was added. The cells were incubated for 5 min on ice. Then, the cells were diluted in culture medium at 371C resulting in a concentration of 0.2 Â 10 6 cells/ml, and cultured for 45 min at 371C under continuous rotation. After washing in cold buffer 20 ml IFNg-detection antibody was added, and the cells were incubated for 10 min on ice. The cells were washed, and resuspended in cold buffer. To exclude dead cells the suspensions were counterstained with propidium iodide (PI) (Sigma, St Louis, USA) at a final concentration of 0.5 mg/ml immediately prior to cell sorting. IFNg-PE positive PI negative cells within the lymphocyte gate were sorted, and plated as single cells per well (single cell/well sorting) using a FACSVantage (BD) into the wells of U-bottom microtiter plates containing 100 ml of feeder-mixture consisting of culture medium, IL2 (100 IU/ml) (Chiron, Amsterdam, The Netherlands), PHA (0.8 mg/ml) (Murex Biotec Limited, Dartford, UK) and 15 Gyirradiated allogeneic PBMC (0.5 Â 10 6 /ml) and irradiated (60 Gy) patient-derived EBV-LCL (0.05 Â 10 6 /ml). After 7 days of culture, 100 ml culture medium and IL2 (100 IU/ml) were added. Proliferating T cell clones were selected, and restimulated with feeder-mixture. From day 23, the clones were functionally analyzed.
Cytotoxicity assay
To determine the cytotoxicity of the T cell clones standard 4 h 51 Cr-release assays were performed as described previously. 39 Patient-or donor-derived PHA blasts, EBV-LCL or leukemic cells were used as target cells. Target cells were labeled with 100 mCi of Na 2 51 CrO 4 , and 5 Â 10 3 target cells were added to the effector cells at E:T ratios ranging from 30:1 to 3:1. T cell clones showing more than 10% specific lysis of target cells were considered cytotoxic. To analyze cytotoxicity against the HA-1 peptide VLHDDLLEA, 18 the HA-2 peptide YIGEVLVSV 19 or the HY-B7 peptide SPSVDKARAEL, 15 donor-derived EBV-LCL were loaded with 1 or 10 mg/ml of peptide during labeling with Na 2 51 CrO 4 for 1 h at 371C.
Hematopoietic progenitor cell inhibition assay (PIA)
The PIA was performed as previously described. 40, 41 As effector cells HA-1, HA-2 and HY-B7 specific CTL clones were used. The anti-HLA-A2 specific CTL clone MBM15 and the HLA-A1 restricted HY-specific CTL clone HY-A1 served as controls. Effector T cells were irradiated (10 Gy) to abrogate T cell proliferation without affecting cytolytic activity. As target cells enriched CD34
þ CML progenitor cells or unfractionated CML mononuclear cells obtained from the patients with CML prior to transplantation, or CD34 þ purified normal hematopoietic progenitor cells (HPC) from the donor were used. Additionally, unfractionated CML mononuclear cells from unrelated HLA-A2 þ , HA-1 or HA-2 positive CML patients were used as target cells. Isolations of CD34
þ CML progenitor cells from the patient PBMC or of CD34 þ HPC from the donor BM cells were performed using CD34 immunomagnetic beads (Miltenyi Biotec GmbH) according to the manufacturer's specifications. Concentrations of 5000 or 10 000 unfractionated CML cells per well, 200 CD34
þ CML cells per well, or 200 donor HPC per well were added to the irradiated effector T cells at E:T ratios ranging from 10:1 to 1:1, in U-bottom microtiter plates. At least 24 wells containing CD34
þ CML cells or donor HPC only were used as a reference. The cells were cultured in 100 ml progenitor cell culture medium consisting of IMDM with 10% human serum, and 100 ng/ml GM-CSF (Novartis, Basel, Switzerland), 100 ng/ ml G-CSF (Amgen, Thousand Oaks, USA), 50 ng/ml IL3 (Novartis), 25 ng/ml SCF (Amgen), 2 IU/ml EPO (Jansen-Cilag, Zug, Switzerland), 0.10 mg/ml transferrin (Serva, Heidelberg, Germany), and 5 Â 10 À5 mmol/l b-mercapto-ethanol (Sigma, St Louis, USA) and 0.5% human albumine (CLB, Amsterdam, The Netherlands). After 6 days of culture [ 3 H]thymidine incorporation was measured to determine the capacity of the T cell clones to inhibit the growth of the CD34 þ CML cells or donor HPC. The following formula was used to calculate the percentage growth inhibition: ((1-experimental cpm/mean cpm reference wells) Â 100%).
TCR VB analysis
RNA was isolated, and oligo(dT) primed cDNA was synthesized using the first-strand cDNA synthesis kit for RT-PCR (AMV) (Roche, Indianapolis, USA). The T cell receptors were amplified using a multiplex amplification where four TCRVB families were amplified in one reaction. Amplification primers were selected based on their specificity for each TCR family and their position to the 3 0 end of the TCRBV region assuring that no overlap between the amplicons of the different TCRs in one amplification reaction could occur. The reverse primer, located in the constant region of the TCR, was labeled with FAM, TET or HEX. Amplifications were performed on a GeneAmp s PCR system 2700 (Applied Biosystems (AB)) using HotGoldStart DNA polymerase (Eurogentec, Seraing, Belgium), 1.5 mM MgCl 2 and 10 ng BSA per reaction. Three PCR reactions, each with a different labeled C primer were mixed. In all, 5 ml of the mixture was analyzed on an ABI PRISM s 310 Genetic analyzer (AB) using Genescan s Analysis Software. PCR products were isolated and sequenced as described previously. 42 Sequences were analyzed using the Sequencing Analysis Softwaret v3.7 (AB). The sequences of the TCRB chains were named according to the nomenclature described by Arden et al. 43 In vitro generation of HA-1 and HA-2 specific CTL from unprimed donors
As responder cells PBMC from unprimed HLA-A2 þ , HA-2 and/ or HA-1 negative donors were used. As stimulator cells autologous DC or monocytes, pulsed with 1 mg/ml HA-1 or HA-2 peptide were used. DC were generated by culturing donor-derived CD34 þ cells in IMDM containing 10% autologous plasma in the presence of 100 ng/ml GM-CSF (Novartis), 2 ng/ml TNFa (Boeringher Ingelheim, Ingelheim am Rhein, Germany) with 20 ng/ml SCF (Amgen). On day 4, 500 IU/ml IL4 (Sheringh Plough, Amstelveen, The Netherlands) was added, and cells were cultured for another 6 days. Monocytes were derived from donor PBMC by counterflow centrifugation. plasma, at a responder:stimulator ratio of 1:5, and after 5 days of culture 60 IU/ml IL2 was added. On day 7 the cells were harvested, CD4 þ T cells were depleted using CD4 immunomagnetic beads (Miltenyi Biotec GmbH) according to the manufacturer's instructions, and the CD8 þ T cells were restimulated with HA-1 or HA-2 peptide pulsed autologous dendritic cells (1:5) or monocytes (1:2). After 28 days of culture and weekly restimulation, with 60 IU/ml IL2 added 24 h after each restimulation, the T cell lines were analyzed for cytolytic activity in the 51 Cr release assay, and the percentage of HA-1 or HA-2 specific CD8 þ T cells in the T cell lines was determined using tetramers.
Results
Clinical response and the presence of activated HLA-DR expressing T cells after DLI Three HLA-A2 expressing, HA-1 and HA-2 positive patients treated for relapsed CML or multiple myeloma with DLI from their HA-2 and/or HA-1 negative donors were included in this study (Table 1 ). In the HLA-A2 and HLA-B7 positive donorrecipient pair 2, HY-disparity was also present in the GVL/GVH direction, allowing the analysis of T cell responses against the HLA-A2 and the HLA-B7 restricted HY antigens. After DLI, patient 1 developed grade I-II GVHD of the skin and liver (serum bilirubin 34 mM/L), and patient 2 developed grade II GVHD of the skin. Both patients were treated with corticosteroids. Patient 3 developed grade I GVHD of the skin and mouth for which no systemic treatment was necessary.
Before DLI, the BCR/ABL transcript levels, expressed as the ratio of BCR/ABL to household gene PBGD mRNA, in the BM of patient 2 and 3 were 1 and 0.1, respectively. Between 5 and 7 weeks after DLI, a rapid decrease in the number of BCR/ABL transcripts occurred, resulting in undetectable levels (p10 À5 ) of BCR/ABL transcripts in BM and PB. In the PB of patient 1 the Mprotein level before DLI was 7 g/l. At 7 weeks after DLI the M-protein had decreased to 5 g/l and at 14 weeks after DLI the M-protein was undetectable (o1 g/l), and no myeloma cells were present in the BM. All three patients converted to 100% donor chimerism.
To determine the activation state of the circulating T cells during the clinical response to DLI in these patients, we analyzed the percentages of HLA-DR expressing CD4 þ and CD8 þ T cells in the PBMC fraction before DLI, and 4-9 weeks after DLI (Table 2 ). Prior to DLI the percentages of the HLA-DR expressing CD4 þ and CD8 þ T cells were relatively low. An increase in the percentages of HLA-DR þ T cells within the CD8 þ T cell population was seen between 4 and 7 weeks after DLI in all three patients. A more limited increase in the percentages of HLA-DR þ T cells within the CD4 þ T cell compartment was found after DLI.
Isolation of leukemia-reactive T cells
To investigate the contribution of HA-1 and HA-2 specific T cells to the total number of leukemia-reactive T cells in these patients, we isolated all tumor-responding T cells, defined by IFNg production, directly from the PBMC samples from patient 1 and 2 at week 6-7 after DLI. From patient 3, tumor-directed T cells were isolated 5 weeks (patient 3A) and 6-7 weeks (patient 3B) after DLI. Figure 1 shows a representative example of the analysis of viable IFNg secreting T cells after 16 h of stimulation. Lymphocytes were gated using the forward scatter and side scatter (Figure 1a ). The staining with PI allowed gating of viable PI negative lymphocytes (Figure 1b) , and the viable IFNg-PE þ cells within the gate R3 ( Figure 1c ) were sorted single cell/well. The percentages of IFNg secreting T cells measured in the purified T cell population from the three patients after 16 h of stimulation ranged from 0.06 to 0.44% (Table 3) , which were much lower than the percentages of HLA-DR þ CD8 þ T cells measured directly in the PB at these same time points (Table 2) . Single cell/well sorting of the viable IFNg-PE þ cells yielded a total of 659, 674, 646 and 632 IFNg-PE þ cells from patient 1, patient 2, patient 3A and patient 3B, respectively (Table 3) . Cr release assay for cytotoxicity against EBV-LCL or PHA blasts from the patients and donors. In total, 66, 11, 19 and 39 T cell clones showed lysis of EBV-LCL and/or PHA blasts from patients 1, 2, 3A and 3B, respectively (Table 3) . No reactivity with donor EBV-LCL or PHA blasts was found (data not shown). All CTL clones were CD8 þ except for 2 CD4 þ CTL clones isolated from patient 3 ( Table 3 ). This correlated with the high percentage of CD8 þ T cells (58-93%) in the responder T cell populations from which the IFNg secreting T cells were cloned, and with the high percentages of CD8 þ T cell clones (75-98%) within the total number of proliferating T cell clones.
Tetramer staining of cytotoxic T cell clones
To determine the frequencies of HA-1 and HA-2 specific clones, all T cell clones that exerted cytolytic activity (CTL clones) were stained with HLA-A2/HA-1 and HA-2 tetramers. CTL clones from patient 2 were also stained with the HLA-A2/HY-A2 and HLA-B7/HY tetramers. Except for clone 3A.3, which showed intermediate HA-2 tetramer staining with a mean fluorescence intensity (MFI) of 28, all tetramer þ CTL clones showed high staining intensities (MFI470) with the HA-1, HA-2 or HY-B7 tetramer (Figure 2 ). CTL clones with MFI below 25 were considered to be tetramer negative.
The numbers HA-1 and/or HA-2 specific CTL clones isolated from each patient as determined by tetramer staining are presented in Table 4 . For patient 2 also the numbers of isolated HY specific CTL clones are included. From patient 1, 19 HA-1 specific T cell clones were isolated, representing 29% of the CTL clones isolated. From patient 2, one of the 11 CTL clones was HA-1 specific. Furthermore, four of the 11 CTL clones were specific for HY-B7, representing 36% of CTL clones isolated. No HY-A2 specific CTL clones were isolated. From patient 3 at 5 weeks after DLI (patient 3A) the tumor-reactive T cells isolated contained four HA-2 specific CTL clones, representing 21% of the total number of isolated tumor-reactive clones, and no HA-1 specific CTL clones. Of the HA-2 specific CTL clones, clone 3A.3 was intermediate tetramer þ . At 6 weeks after DLI (patient 3B) the isolation of tumor-reactive T cells yielded 1 HA-1 For patient 1, 2 and 3B isolation was performed from the PB samples taken at 6-7 weeks after DLI, and for patient 3A isolation was performed from the PB sample taken at 5 weeks after DLI.
Figure 2
Staining of representative CTL clones with the HLA-A2/HA-1 and HA-2 or the HLA-B7/HY tetramers. Tetramer þ CTL clones showed high MFI staining with the tetramers (MFI470).
n Only clone 3A.3 showed intermediate staining (MFI ¼ 28) with the HA-2 tetramer. CTL clones with MFIo25 were defined as tetramer negative. Representative examples of tetramer þ and tetramer negative CTL clones are shown.
Dominance of HA-1 and HA-2 specific T cells after DLI FM Kloosterboer et al specific clone and 13 HA-2 specific clones, representing 3 and 33% of the total number of CTL clones isolated, respectively.
Cytolytic capacity of HA-1 and HA-2 specific CTL clones
To confirm the specificity that was determined by tetramer staining, the HA-1, HA-2 and HY-B7 tetramer þ T cell clones were tested for cytotoxic activity against autologous donorderived target cells pulsed with relevant or irrelevant peptides. As shown in Figure 3 , all HA-1, HA-2 and HY-B7 specific CTL clones isolated from the different patients efficiently lysed donor target cells when loaded with the relevant peptide and not after loading with an irrelevant peptide confirming their antigen specificity. The intermediate affinity HA-2 specific CTL clone showed lower lysis as compared to the high affinity HA-2 specific CTL.
To determine the cytolytic activity of the HA-1, HA-2 and HY-B7 specific CTL clones against normal hematopoietic target cells from the patient that endogenously expressed the mHag, we analyzed the cytolytic activity of the CTL clones against PHA blasts and/or EBV-LCL from the patients and donors. As illustrated in Figure 4 , all HA-1, HA-2 and HY-B7 specific CTL clones isolated from the different patients lysed PHA blasts and/ or EBV-LCL from the patients whereas no cytolytic activity against donor-derived target cells was found for any of the CTL clones (o10% lysis). As compared to the high tetramer þ HA-2 specific T cells, the intermediate tetramer þ HA-2 specific CTL clone from patient 3A showed lower lysis of patient EBV-LCL and did not lyse patient-derived PHA blasts.
In summary, the mHags HA-1 and HA-2 specific T cell clones as well as the HY-B7 specific T cell clones isolated efficiently lysed target cells pulsed with the relevant peptide and normal hematopoietic target cells endogenously expressing the mHag but not donor-derived target cells.
Reactivity against leukemic cells
The HA-1, HA-2 and HY-B7 specific CTL clones isolated from patient 2 and 3 were tested for reactivity against CML cells from the patients and against normal HPC from the donors in a 51 Crrelease assay and/or in the hematopoietic progenitor cell inhibition assay. From patient 1 no sufficient purified multiple myeloma cells could be obtained to perform this analysis. The HA-1 and HA-2 specific CTL clones from patient 2 and 3 showed no reactivity against normal donor HPC in the 51 Crrelease assay or in the hematopoietic progenitor cell inhibition assays (data not shown). Figure 5 demonstrates that the HA-1 and HY-B7 specific CTL clones isolated from patient 2 as well as the control HLA-A2 allospecific CTL clone MBM15 showed cytolytic activity against the CML cells from unfractionated PBMC in the 51 Cr-release assay with lysis up to 25%. In addition, these clones strongly inhibited the growth of malignant recipient precursor cells from unfractionated PBMC. The HLA-A1 restricted HY-specific CTL HY-A1 clone that was included as a negative control showed no cytolytic activity against the recipient CML cells or growth inhibition of the malignant recipient precursor cells. Since the hematopoietic progenitor cell inhibition assay provides a more sensitive and relevant measurement of reactivity against leukemic cells as compared to the 51 Cr-release assay 40, 41 the HA-1 and HA-2 specific CTL clones from patient 3B were only analyzed for reactivity against leukemic cells in the progenitor cell inhibition assay. As shown in Figure 6a , the HA-1 specific CTL clones, the HA-2 specific CTL clones and the HLA-A2 allospecific CTL clone MBM15 showed strong growth inhibition of enriched CD34 þ leukemic progenitor cells from the recipient whereas the HLA-A1 Table 4 Relative contribution of HA-1, HA-2 and HY-B7 specific CTL clones to the total number of isolated CTL clones from patient 1-3 
Figure 3
Percentage lysis of peptide-pulsed targets by the HA-1, HA-2 and HY-B7 specific CTL clones. CTL clones were tested for lysis of donor PHA blasts (patient 1) or EBV-LCL (patient 2 and 3) pulsed with HA-1 peptide, HA-2 peptide or HY-B7 peptide, at an ET ratio of 10:1. The different mHag specificities of the CTL clones are indicated by the arrows. The HA-1 specific CTL clones from patient 1 (a), the HA-1 and HY-B7 specific CTL clones from patient 2 (b), the HA-2 specific CTL clones from patient 3A (c) and the HA-1 and HA-2 specific CTL clones from patient 3B (d) only recognized donor target cells loaded with the relevant peptide and not when loaded with an irrelevant peptide. The intermediate tetramer þ HA-2 specific CTL clone 3A.3 from patient 3A showed lower cytotoxicity against the HA-2 peptide pulsed donor-derived EBV-LCL as compared to the other HA-2 specific CTL clones isolated from this patient.
restricted HY-specific CTL clone showed no reactivity. To exclude the possibility of nonspecific suppression of progenitor cell growth, representative examples of HA-1 and HA-2 specific CTL clones as well the HLA-A1-restricted HY-specific CTL clone HY-A1 were analyzed for reactivity against malignant progenitor cells from an HLA-A1 þ , HLA-A2 þ male CML patient that expressed HA-1 but not HA-2 (Figure 6b) or from an HLA-A1 À , HLA-A2 þ male CML patient that expressed HA-2 but not HA-1 (Figure 6c ). The HA-1 specific CTL clone and HA-2 specific CTL clones only recognized the malignant progenitor cells when the relevant mHag was expressed, illustrating that the target cell recognition was antigen-specific. The HLA-A1 restricted HYspecific CTL clone HY-A1 that did not recognize the progenitor cells from female patient 3 (Figure 6a) , did recognize the progenitor cells from the HLA-A1 Percentage lysis of normal hematopoietic cells from donor and patient by the HA-1, HA-2 and HY-B7 specific CTL clones. The clones were tested against recipient-derived or donor-derived PHA blasts and/or recipient-derived and donor-derived EBV-LCL in a standard 4-h 51 Cr release assay at an ET ratio of 30:1 or 10:1 n . The arrows indicate the different mHag specificities of the CTL clones. The HA-1 specific CTL clones from patient 1 (a), the HA-1 and HY-B7 specific CTL clones from patient 2 (b), the HA-2 specific CTL clones from patient 3A (c) and the HA-1 and HA-2 specific CTL clones from patient 3B (d) only lysed recipient-derived PHA blasts and/or EBV-LCL, and not donor-derived PHA blasts and EBV-LCL. The intermediate tetramer þ HA-2 specific CTL clone 3A.3 from patient 3A did not lyse the recipient derived PHA blasts and showed lower cytotoxicity against the recipient derived EBV-LCL as compared to the other HA-2 specific CTL clones isolated from this patient.
Figure 5
Reactivity of HA-1 and HY-B7 specific CTL clones from patient 2 against patient leukemic cells. The percentage lysis of patient leukemic cells from unfractionated PBMC was measured in the 51 Cr release assay (white bars) and the percentage growth inhibition of CML progenitor cells from unfractionated PBMC was measured in the hematopoietic progenitor cell inhibition assay (black bars) at ET ratio 3:1. The anti HLA-A2 CTL clone MBM15 was included as a positive control and the HLA-A1 restricted HY-specific CTL clone HY-A1 was included as a negative control. TCRBV chain usage of HA-1 and HA-2 specific CTL clones
The TCRBV chain usages of the HA-1 specific CTL clones from patient 1 and the HA-2 specific CTL clones from patient 3B were analyzed by PCR using TCRBV family specific oligonucleotides and sequencing of the TCRBV specific PCR products. Only CTL clones from which T cell samples could be obtained that were free of irradiated allogeneic feeder cells that could interfere with accurate analysis, were analyzed. Analysis of 13 of the 19 HA-1 specific CTL clones from patient 1 showed that these CTL clones all used the BV6S4 TCR but DNA sequence analysis showed the presence of two types of BV6S4 TCR among the CTL clones, which differed in the BV region, the N-nucleotides and the J-region (data not shown). Thus, two different types of T cell clones with unique clonal origins were found. Among the four HA-2 specific CTL clones analyzed from patient 3B, three different types of TCR were found (data not shown).
In vitro generation of HA-1 and HA-2 specific T cells from the unprimed donors
To analyze whether HA-1 and HA-2 specific T cells could also be generated in vitro from the PB of unprimed HA-1 and/or HA-2 negative donors by direct isolation of mHag reactive T cells on the basis of IFNg secretion, purified T cells from an HLA-A2 þ , HA-1 negative, HA-2 positive donor were stimulated with autologous monocyte-derived DC pulsed with HA-1 peptide, and after 16 h of stimulation the IFNg secreting T cells were stained using the IFNg secretion assay. The percentage of IFNg secreting T cells after stimulation with HA-1 peptide pulsed DC was low (o0.02%) and comparable to the percentage of IFNg secreting T cells in the unstimulated T cell fraction. Additionally, HA-1 and/or HA-2 tetramer analysis of the PB of HLA-A2 þ , HA-1 and/or HA-2 negative donors (n ¼ 4), including the donors from donor-recipient pair 2 and 3, showed that the frequency of HA-1 and/or HA tetramer positive CD8 þ T cells was undetectable (o0.02%). These data indicated that the frequency of IFNg secreting T cells in the PB of HA-1 and/or HA-2 negative donors after HA-1 or HA-2 mHag specific stimulation was too low to allow direct isolation of HA-1 or HA-2 specific T cells from the PB of unprimed HLA-A2 þ , HA-1 and/or HA-2 negative donors on the basis of IFNg secretion after mHag specific stimulation.
To determine whether HA-1 and/or HA-2 specific T cells could be generated in vitro from the unprimed HLA-A2 þ , HA-2 and/or HA-1 negative donors after repeated antigen-specific stimulation, PBMC from the donors from donor-recipient pairs 2 and 3 were stimulated with autologous DC pulsed with HA-1 or HA-2 peptide. After 28 days of culture and weekly restimulation with peptide pulsed monocytes or DC as APC, the T cell lines were analyzed for cytolytic activity, and for the presence of HA-1 or HA-2 specific CD8 þ T cells. From donor 2, a T cell line was generated by stimulation with HA-1 peptide pulsed APC (Figure 7a) , and from donor 3, T cell lines were generated by stimulation with APC pulsed with HA-1 peptide (Figure 7b ) or HA-2 peptide (Figure 7c) . The three T cell lines were cytolytic against patient-derived PHA blasts and donor-derived PHA blasts when pulsed with the relevant peptide. Furthermore, the T cell line from donor 2 showed low cytolytic activity against the leukemic cells from patient 2. The cytolytic activity of the T cell lines from donor 3 against the leukemic cells could not be determined since insufficient CML cells from patient 3 were available. HA-1 tetramer analysis of the HA-1 reactive CTL lines showed 6 and 16% HA-1 tetramer þ CD8 þ T cells within the cell lines from donor 2 and 3, respectively.
Discussion
Based on the potential immunodominant nature and the hematopoiesis restricted tissue distribution of the mHags HA-1 and HA-2, we hypothesized that in HLA-A2 and HA-1 and/or HA-2 positive patients with relapsed disease after SCT who were treated with DLI from their HA-1 and/or HA-2 negative donor, T cells specific for HA-1 and HA-2 would significantly contribute to the clinical response to DLI.
Using tetrameric HLA/mHag complexes we recently showed that the complete remission and restoration of 100% donor chimerism in patients treated for relapsed malignancy after SCT with DLI from their HA-2 and/or HA-1 disparate donor was accompanied by the emergence of HA-2 tetramer þ and/or HA-1 tetramer þ CD8 þ T cells in the PB. 35 The frequencies of HA-1 tetramer þ and HA-2 tetramer þ CD8 þ T cells in the PB of these patients were much lower than the frequencies of activated HLA-DR-expressing T cells in the PB. However, in vivo HLA-DR positive T cells reflect all activated T cells, including T cells that are triggered by inflammatory responses due to infections and GVHD. Since the total frequency of tumor-reactive T cells within the total population of activated HLA-DR þ T cells could not be measured using this approach, the relative contribution of HA-1 and HA-2 specific T cells to the GVL reactivity could not be determined.
The aim of the present study was to quantify the relative contribution of HA-1 and HA-2 specific T cells within the total population of activated leukemia-directed T cells in patients after DLI from their HA-2 and/or HA-1 disparate donors. Leukemia-directed T cells were isolated on the basis of IFNg secretion since tumor-reactive T cells generally secrete IFNg [45] [46] [47] and, as we recently showed, HA-2 specific CTL clones isolated by cell sorting using HA-2/HLA-A2 tetrameric complexes and expanded nonspecifically, all produced high amounts of IFNg. 42 Similarly, all HA-1 tetramer positive CTL Dominance of HA-1 and HA-2 specific T cells after DLI FM Kloosterboer et al clones isolated from this patient using HA-1/HLA-A2 tetrameric complexes also produced IFNg (data not shown).
Three donor-recipient pairs were included in this study. This seemingly low number is due to the fact that only 10% of donor-recipient pairs is HLA-A2 þ and incompatible for HA-1 in the GVL/GVHD direction, and an even lower percentage of donor-recipient pairs is incompatible for HA-2 in this direction. Together with the frequent blood sampling that is required for the analysis, three of the four patients that were treated with DLI from their HA-2 and/or HA-1 incompatible donor were eligible for this study.
A selection procedure was developed that allowed direct measurement in PB of the total immune response against the malignant cells. Based on the kinetics of the clinical immune responses, as was measured by the in vivo antitumor effect in combination with the presence of activated HLA-DR expressing T cells, leukemia-reactive T cells were isolated based on IFNg secretion, and directly cloned. The percentages of IFNg secreting T cells after stimulation with the malignancy represented only small fractions of the percentages of HLA-DR þ T cells, suggesting that only a small fraction of the activated HLA-DR þ T cells was reacting against the malignancy. Single-cell sorting of the IFNg-producing cells resulted in a high clonal expansion efficiency of 10-30% of the cells isolated. A high percentage (11-59%) of these T cell clones exhibited patientspecific cytotoxicity. Most T cells responding to the malignancy by producing IFNg were CD8 þ T cells, which correlated with the high percentages of CD8 þ T cells within the responder T cell populations from which the IFNg secreting T cells were isolated. The majority of the CD4 þ T cell clones that were isolated was not cytotoxic. These noncytolytic IFNg producing CD4 þ T cells that were isolated may have contributed to the clinical response to DLI by the secretion of other cytokines that play a role in generating an effective CD8 þ T cell response. Tetramer analysis of the CTL clones showed that between 3 and 35% of the CTL clones isolated from each patient were specific for HA-1 or HA-2. Considering the likelihood that multiple mHag disparities were present between a particular donor-recipient combination, the percentages of HA-1 and HA-2 specific T cell clones obtained within the total leukemiareactive T cell population were relatively high.
To determine whether the HA-1 and HA-2 specific CTL clones isolated represented unique clonal T cell responses against HA-1 and HA-2, or the presence of a limited number of immunodominant T cell clones, the TCR B usage of the HA-1 and HA-2 specific CTL clones was analyzed. The analysis showed that the responses against HA-1 and HA-2 were oligoclonal with various T cell clones present at different frequencies in PB. We found a restricted TCR BV6 usage for the HA-1 specific CTL clones which is one of the characteristics of HA-1 specific T cells as has been demonstrated earlier for both in vivo and ex vivo generated HA-1 specific CTL. 48, 49 To illustrate that the HA-1 and HA-2 specific CTL clones could contribute to the GVL response, the reactivity of the HA-1 and HA-2 specific CTL clones against the leukemic cells was measured. In the 51 Cr release assay, only low reactivity against the leukemic cells was found for the HA-1 and HA-2 specific T cell clones. This was however also found for the HLA-A2 directed allogeneic CTL clone MBM15. The limited lysis measured in the 51 Cr release assay is probably due to the relative insensitivity of mature myeloid cells to lysis by CTL. Similar to our previous studies showing that the hematopoietic progenitor cell inhibition assay is more sensitive than the 51 Cr release assay to measure reactivity against leukemic progenitor cells, 40 ,41 the HA-1 and HA-2 specific CTL clones showed strong antigen-specific reactivity against the CML progenitor cells in the progenitor cell inhibition assay, demonstrating their potential role in the in vivo GVL response. Since no sufficient purified multiple myeloma cells could be isolated from patient 1, reactivity of the HA-1 specific CTL clones from patient 1 against the multiple myeloma cells could not be determined. However, we recently showed that the HA-1 gene product is present at the transcriptional level in multiple myeloma cells, 26 indicating that HA-1 specific T cells may have contributed to the graft-versus-myeloma response in this patient. In addition to the HA-1 and HA-2 specific CTL clones in patient 2, also the HY-B7 specific CTL clones specifically recognized leukemic cells and inhibited the growth of leukemic progenitor cells and therefore have also likely contributed to the GVL response. The number of HY-B7 specific CTL clones exceeded the number of HA-1 specific CTL clones among the tumor-reactive T cell response. The relatively high frequency of circulating HY-B7 specific T cells may be caused by a high expression of HY-B7 on the tumor cells, or by the ubiquitous expression of the mHag HY-B7. The presence of HY-B7 specific T cells may have contributed substantially to the presence of significant GVHD observed in this patient 6 weeks after DLI. In patient 1 and 3 no HY-disparity was present in the GVL/GVH direction and more limited GVHD was observed at the time of analysis.
Our results indicate that in vitro generated donor-derived HA-1 or HA-2 specific CTL clones may be used to specifically eliminate the leukemic cells after allogeneic SCT without inducing severe GVHD. Therefore, we analyzed whether the direct clonal isolation procedure could also be used to isolate HA-1 or HA-2 specific CTL from the unprimed HLA-A2 þ , HA-1 and/or HA-2 negative donors. In line with the low or undetectable frequencies of HA-1 and/or HA-2 tetramer þ
CD8
þ T cells measured in PB of these donors, the frequency of IFNg secreting T cells in the unprimed HLA-A2 þ , HA-1 negative donor was too low to allow isolation using the direct cloning procedure. However, it was possible to generate donorderived T cell lines that contained HA-1 or HA-2 tetramer þ T cells by prolonged culture and HA-1 or HA-2 mHag-specific stimulation. These in vitro generated HA-1 or HA-2 specific T cells were capable of lysing patient-derived normal hematopoietic target cells, donor-derived target cells when pulsed with the relevant peptide, and also leukemic cells. 50 In conclusion, during the clinical response to DLI from HA-2 and/or HA-1 disparate donors a high percentage of the tumorreactive T cells in the recipient was directed against HA-1 or HA-2, and displayed strong reactivity against the recipient leukemic progenitor cells demonstrating the immunodominant nature of these mHags, and the important role of HA-1 and HA-2 specific T cells in the antileukemic reactivity that is observed after DLI. Furthermore, we showed that it was possible to generate HA-1 or HA-2 specific T cells from the unprimed HLA-A2 þ , HA-1 or HA-2 negative donors. This study supports the idea that adoptive immunotherapy with in vitro generated HA-1 and HA-2 specific CTL would be effective in more specifically eliminating the leukemic cells after allogeneic SCT.
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